Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial

Authors:

Abstract
No abstract available
Funding Information
  • Merck Sharp and Dohme Ltd

This publication has 20 references indexed in Scilit: